Dr. Weiping Zou
Dr. Weiping Zou, M.D., Ph.D.
Professor, Surgery, Immunology and Biology
University of Michigan Health Systems
Dr. Weiping Zou, M.D., Ph.D.
Professor, Surgery, Immunology and Biology
University of Michigan Health Systems
Education
B.A.: Tongji Medical School (1987)
M.D.: Tongji Medical School (1990)
Ph.D.: University of Paris (1997)
Research Interests
Weiping Zou, M.D., Ph.D. is the Charles B. de Nancrede Professor of Surgery, Immunology and Biology, and Director of Translational Research within the Department of Surgery, and Co-Director of Tumor Immunology & Host Defense Program at the University of Michigan Comprehensive Cancer Center. He has an international reputation in human tumor immunology and immunotherapy. His prior research efforts demonstrate that the tumor microenvironment is comprised of immune cells that have been reprogrammed by active tumor-mediated processes to defeat tumor-specific immunity and promote tumor growth in a highly effective manner. These studies have examined different cellular and molecular components of the immune suppressive networks, and defined the nature of immune responses in the tumor microenvironment, and provide significant new insights into designing novel anti-cancer immune therapies including current inhibitory B7 (PD-L1/PD-1) check-point blockade. As such, the Zou laboratory has published more than 100 research articles and book chapters including 14 articles published in the series of journals of Nature, Science and Cell. The Zou team is one of the most cited research teams in the field of immunology. The single original work on human cancer associated Treg cells has been cited for more than 3,000 times. He is among the most highly-funded investigators in this country. He is/was an Associate Editor of the Journal of Immunology, a consulting editor of the Journal of Clinical Investigation, and the editorial boards of 5 cancer research journals. He is often a reviewer for more than 30 scientific journals and for more than 10 funding agencies including NIH. He has accepted major invitations and delivered nearly 200 seminars.
Links
Laboratory website
OCRF Grant Recipient
B.A.: Tongji Medical School (1987)
M.D.: Tongji Medical School (1990)
Ph.D.: University of Paris (1997)
Research Interests
Weiping Zou, M.D., Ph.D. is the Charles B. de Nancrede Professor of Surgery, Immunology and Biology, and Director of Translational Research within the Department of Surgery, and Co-Director of Tumor Immunology & Host Defense Program at the University of Michigan Comprehensive Cancer Center. He has an international reputation in human tumor immunology and immunotherapy. His prior research efforts demonstrate that the tumor microenvironment is comprised of immune cells that have been reprogrammed by active tumor-mediated processes to defeat tumor-specific immunity and promote tumor growth in a highly effective manner. These studies have examined different cellular and molecular components of the immune suppressive networks, and defined the nature of immune responses in the tumor microenvironment, and provide significant new insights into designing novel anti-cancer immune therapies including current inhibitory B7 (PD-L1/PD-1) check-point blockade. As such, the Zou laboratory has published more than 100 research articles and book chapters including 14 articles published in the series of journals of Nature, Science and Cell. The Zou team is one of the most cited research teams in the field of immunology. The single original work on human cancer associated Treg cells has been cited for more than 3,000 times. He is among the most highly-funded investigators in this country. He is/was an Associate Editor of the Journal of Immunology, a consulting editor of the Journal of Clinical Investigation, and the editorial boards of 5 cancer research journals. He is often a reviewer for more than 30 scientific journals and for more than 10 funding agencies including NIH. He has accepted major invitations and delivered nearly 200 seminars.
Links
Laboratory website
OCRF Grant Recipient